Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

0.9700 +0.0500 (+5.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Femasys Inc. - Common Stock

< Previous 1 2 3 Next >
5 of the Most Active Penny Stocks Worth Your Precious Time
These are five of the Most Active Penny Stocks in October that investors may find worthy of investment for 2024 and beyond 
Via MarketBeat
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
From Femasys Inc.
Via GlobeNewswire
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Obtains Medical Device Establishment License from Health Canada
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial - 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
From Femasys Inc.
Via GlobeNewswire
Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
From Femasys Inc.
Via GlobeNewswire
Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
From Femasys Inc.
Via GlobeNewswire
Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Femasys Inc.
Via GlobeNewswire
Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
Company remains on track to file an investigational device exemption (IDE) for a pivotal trial to support a pre-market authorization (PMA) in the first quarter of 2023 
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
From Femasys Inc.
Via GlobeNewswire
IPO Launch: 31.6 Million Dollar Raised; Clinical Trials Underway on Key Female Oriented Healthcare Advances: Femasys (NASDAQ: FEMY)
Via Get News
Topics Initial Public Offering
Clinical Trials Underway on Key Female Oriented Healthcare Advances from new IPO Launch: Femasys (NASDAQ: FEMY)
Via Get News
Topics Initial Public Offering
Woman-Lead BioPharma Starts Clinical Trials on Key Female Oriented Healthcare Advances: Femasys (NASDAQ: FEMY)
Via Get News
Topics Initial Public Offering
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.